Lecturer on Medicine, VA, VFW Parkway WestRox
Cardiology
Dr. Philip J. Podrid, MD
|
|
Give Review
Philip Podrid is an expert in the field of Cardiology. He went to NYU School of Medicine. He over the years received 1 awards: "Fellow (FACC)". Philip Podrid has written publications. He has 101 publications published with PubMed. The lastest paper is: 'Aggravation of arrhythmia: a complication of antiarrhythmic drugs.'
Publications
- Response to Letter Regarding Article, "ECG Response: May 20, 2014".
- Epidemiology and stratification of risk for sudden cardiac death.
- Effect of a digitalis drug on ventricular premature beats.
- Hyperthyroidism after propranolol withdrawal.
- Therapy with and assessment of class III antiarrhythmic agents in different patient populations.
- Evaluating patients with ventricular arrhythmia. Role of the signal-averaged electrocardiogram, exercise test, ambulatory electrocardiogram, and electrophysiologic stu...
- Aggravation of arrhythmia by antiarrhythmic drugs, and the important role of underlying ischemia.
- Ventricular arrhythmia in congestive Heart failure.
- Efficacy and safety of moricizine in patients with congestive Heart failure: a summary of the experience in the United States.
- Evaluation of cardiac Arrhythmias by exercise testing.
- [Proarrhythmic effects of anti-arrhythmia agents].
- Antiarrhythmic drug therapy: evaluation and modification of treatment.
- Safety and toxicity of antiarrhythmic drug therapy: benefit versus risk.
- Moricizine (ethmozine HCl)--a new antiarrhythmic drug: is it unique?
- Left ventricular dysfunction and ventricular Arrhythmias: reducing the risk of sudden death.
- Comparative cost-effectiveness analysis of quinidine, procainamide and mexiletine.
- Role of the Sympathetic nervous system in the genesis of ventricular arrhythmia.
- Side effects from amiodarone.
- Role of combination drug therapy with a class IC antiarrhythmic agent and mexiletine for ventricular tachycardia.
- An analysis of the cost effectiveness of the implantable defibrillator.
- Potassium and ventricular Arrhythmias.
- Noninvasive diagnosis of ventricular Arrhythmias by means of ambulatory-ECG monitoring.
- Should asymptomatic ventricular arrhythmia in patients with congestive Heart failure be treated? An antagonist's viewpoint.
- Pharmacologic therapy for Arrhythmias: attention to the benefit-risk ratio.
- The oral antiarrhythmic drugs.
- Silent ischemia, ventricular arrhythmia and sudden cardiac death.
- Antiarrhythmic drug therapy for congestive Heart failure with focus on moricizine.
- The role of antiarrhythmic drugs in prevention of sudden cardiac death.
- Aggravation of arrhythmia by antiarrhythmic drugs--incidence and predictors.
- Noninvasive evaluation of indecainide for serious ventricular tachyarrhythmia.
- Therapeutic and diagnostic benefits of intentional crosstalk mediated ventricular output inhibition.
- Biventricular function during postextrasystolic potentiation in man. A study using list-mode radionuclide ventriculography.
- Encainide and flecainide: are they interchangeable?
- Congestive Heart failure induced by six of the newer antiarrhythmic drugs.
- Lessons to be learned from the cardiac arrhythmia suppression trial.
- Effect of age on antiarrhythmic drug efficacy and toxicity.
- Aggravation of arrhythmia: a complication of antiarrhythmic drug therapy.
- Resuscitation in the elderly: a blessing or a curse?
- Antiarrhythmic drug therapy (Part 1). Benefits and hazards.
- The role of beta blocking agents as adjunct therapy to membrane stabilizing drugs in malignant ventricular arrhythmia.
- The role of exercise testing in evaluation of Arrhythmias.
- Practical follow-up guidelines for patients treated with amiodarone.
- Short- and long-term therapy with tocainide for malignant ventricular tachyArrhythmias.
- Mexiletine and tocainide: does response to one predict response to the other?
- Safety and efficacy of encainide for malignant ventricular Arrhythmias.
- Clinical predictors of arrhythmia worsening by antiarrhythmic drugs.
- Electrophysiologic testing in arrhythmia.
- Side effects and complications of amiodarone therapy.
- Ethmozine (moricizine HCl) therapy for complex ventricular Arrhythmias.
- Effects of Ethmozine (moricizine HCl) on ventricular function using echocardiographic, hemodynamic and radionuclide assessments.
- Intravenous lorcainide for symptomatic ventricular tachyArrhythmias: comparison with lidocaine and oral lorcainide.
- Spontaneous reversion of ventricular Fibrillation.
- Determinants of survival in patients with malignant ventricular arrhythmia associated with Coronary artery disease.
- Spontaneous variability and circadian distribution of ectopic activity in patients with malignant ventricular arrhythmia.
- Historic perspectives--electrical stimulation of the Heart.
- Antiarrhythmic drug selection.
- Proarrhythmia, arrhythmogenesis or aggravation of arrhythmia--a status report, 1987.
- Predictors of antiarrhythmic drug efficacy in patients with malignant ventricular tachyArrhythmias.
- Considerations of current methods for drug selection in treating malignant ventricular Arrhythmias.
- Exercise stress testing for exposure of Arrhythmias.
- Aggravation of ventricular arrhythmia. A drug-induced complication.
- Antiarrhythmic drug therapy (Part 2). Benefits and hazards.
- Daily reproducibility of electrophysiologic test results in malignant ventricular arrhythmia.
- Use of short-term drug testing as part of a systematic approach for evaluation of antiarrhythmic drugs.
- Relationship between ease of inducibility of arrhythmia with electrophysiologic testing and response to antiarrhythmic therapy.
- Treatment of ventricular arrhythmia. Applications and limitations of noninvasive vs invasive approach.
- Aggravation of arrhythmia induced with antiarrhythmic drugs during electrophysiologic testing.
- Drug-associated diarrhoea as a potential reservoir for hospital infections.
- Role of higher nervous activity in ventricular arrhythmia and sudden cardiac death: implications for alternative antiarrhythmic therapy.
- Sudden cardiac death--management of the patient at risk.
- Aggravation and provocation of ventricular Arrhythmias by antiarrhythmic drugs.
- Long-term survival of patients with malignant ventricular arrhythmia treated with antiarrhythmic drugs.
- Encainide for refractory ventricular tachyarrhythmia.
- Ventricular postextrasystolic potentiation in the dog. A study using list mode radionuclide ventriculography.
- Postextrasystolic potentiation during spontaneous ventricular ectopy in man. Associated left ventricular volume changes determined by list mode radionuclide ventriculo...
- Propafenone: a new agent for ventricular arrhythmia.
- Management of malignant ventricular arrhythmia--experience with lorcainide.
- Effects of oral mexiletine on left and right ventricular function.
- Can antiarrhythmic drugs cause arrhythmia?
- Exercise stress testing in the management of cardiac rhythm Disorders.
- Propafenone: noninvasive evaluation of efficacy.
- Efficacy of amiodarone for refractory supraventricular tachyArrhythmias.
- Sudden cardiac death--an approach to management of the patient at risk.
- Lorcainide in patients with refractory ventricular tachyarrhythmia.
- Effects of acetyl-strophanthidin on left ventricular function and ventricular Arrhythmias.
- Long-term mexiletine for ventricular arrhythmia.
- Mexiletine for ventricular Arrhythmias.
- Tocainide for refractory symptomatic ventricular Arrhythmias.
- Use of radionuclide ventriculography for assessment of changes in Myocardial performance induced by disopyramide phosphate.
- Use of nonsustained ventricular tachycardia as a guide to antiarrhythmic drug therapy in patients with malignant ventricular arrhythmia.
- Cardioversion and deFibrillation.
- Pindolol for ventricular arrhythmia.
- Amiodarone therapy in symptomatic, sustained refractory atrial and ventricular tachyArrhythmias.
- Prognosis of medically treated patients with Coronary-artery disease with profound ST-segment depression during exercise testing.
- Ethmozin, a new antiarrhythmic drug for suppressing ventricular premature complexes.
- Congestive Heart failure caused by oral disopyramide.
- Amiodarone: reevaluation of an old drug.
- Right Coronary artery stenosis: an independent predictor of atrial fibrillation after Coronary artery bypass surgery.
- Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in Acute myocardial infarction treated with recom...
- Aggravation of arrhythmia: a complication of antiarrhythmic drugs.
Schools
New York University
Montefiore Med Center
Bellevue Hospital Center
Peter Bent Brigham Hospital
Conditions Treated
- Angina and Acute Coronary Syndrome
- Aortic Aneurysm
- Aortic Valve Disease
- Arrhythmias (incl. Atrial Fibrillation)
- View All
Doctors Specialties
- Cardiology
Accepted Insurances
Awards
- Fellow (FACC)
Education
-
Brigham and Women's Hospital -
NYU School of Medicine -
Albert Einstein - Montefiore Medical Center
Hospital
-
Boston Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Thomas P. Rocco, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jayashri R. Aragam, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gummuluru V. Sharma, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jacqueline S. Danik, MD |
|
|
Dr. Peter S. Hoffmeister, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard J. Shea, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael A. Rosenberg, MD
This Doctor is OpenDoctor Recommended.
|